Oof, FibroGen's been through the wringer. A reverse split and China sale? That's a major reset. 📉 The stock is drowning in an oversold RSI below 25, and it's trading below both key WMAs. This looks like a classic "show me" story—the news is all cleanup, no catalyst. Until they prove the new cancer drug is a winner, this is a hard SELL. #FallingKnife

China just greenlit the AstraZeneca buyout of their unit for $160M. That's a massive cash infusion! 📈 The stock ripped from $9 to over $11 on the news, and the 9-day EMA just blasted past the 21-day. RSI cooled from overbought to a still-strong ~69. This looks like a classic "sell the rumor, buy the news" play, and the news just dropped. I'm calling this a BUY on the momentum. #CashInfusion

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FibroGen, Inc. FGEN: 8.42 USD

Bullish views

Bearish views